Biosupply Trends Marketplace News
Monday, November 18, 2019
biosupply button green pixel top of biosupply button
Biosupply, place your product order MyFluVaccine, place your vaccine order Verified Inventory Program, sign up for streamlined inventory

Measles Virus Destroys Immune System's Memory of Past Infections

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

With the resurgence in measles epidemics worldwide, researchers conducted two studies to determine whether measles infection causes long-term damage to immune memory and found it can greatly diminish previously acquired immune memory, potentially leaving individuals at risk for infection by other pathogens. The reduction in humoral immune memory after measles infection generates potential vulnerability to future infections, underscoring the need for widespread vaccination. read more ]

CDC Analyses Show Flu Vaccine Reduces Risk of Hospitalization in Children and Death in Adults

Two analyses by the Centers for Disease Control and Prevention (CDC) show the influenza (flu) vaccine can reduce the likelihood of hospitalization in children and death in adults. Specifically, the vaccine effectiveness against influenza-associated hospitalizations in children was 50 percent over two seasons, and in adults 18 years and older, the vaccine reduced their odds of severe outcomes, including death (36 percent), pneumonia (17 percent), intensive care unit (19 percent) and mechanical ventilation (34 percent). read more ]

Study Finds Safe Treatment for Children with Severe Hemophilia A with Inhibitors

A Phase III study has found a trivalent hepatitis B virus vaccine demonstrated superiority in adults 45 years and older and noninferiority in adults older than 18 years compared with a monovalent vaccine.
read more ]

Industry News

 
Industry News Image
 

From Octapharma USA

The U.S. Food and Drug Administration has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on-demand treatment and control of bleeding episodes. read more ]

From KORU Medical Systems

On Oct. 24, RMS Medical Products rebranded as KROU Medical Systems. The company's email address changed to the domain @korumedical.com and its homepage is now www.korumedical.com.  [ read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     

What's New at FFF

Ambrisentan  (Par Pharmaceutical)

Ambrisentan film-coated tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). It is supplied in 5 mg and 10 mg tablet strengths and is available in the following package configurations: 5 mg 10 count bottle, 5 mg 30 count bottle, 10 mg 10 count bottle and 10 mg 30 count bottle.

For more information about Ambrisentan, log in to biosupply.fffenterprises.com

Bosentan  (Par Pharmaceutical)

Bosentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%). It is available as a 62.5 mg tablet in a bottle containing 60 tablets and a 125 mg tablet in a bottle containing 60 tablets.

For more information about Bosentan, log in to biosupply.fffenterprises.com

Treprostinil  (Par Pharmaceutical)

Treprostinil injection is a prostacyclin vasodilator indicated for pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension in patients requiring transition from epoprostenol. It is supplied in 20 mL multidose vials as sterile solutions in water for injection, individually packaged in cartons, and is available in 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL concentrations.

For more information about Treprostinil, log in to biosupply.fffenterprises.com

KOATE  (Kedrion)

KOATE is indicated for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of clotting factor VIII. Koate provides a means of temporarily replacing the missing clotting factor to control or prevent bleeding episodes, or to perform emergency and elective surgery on individuals with hemophilia. It is supplied in a kit containing one single-use vial of Koate lyophilized powder, one vial of sterile water for injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set.

For more information about KOATE, log in to biosupply.fffenterprises.com

ELCYS  (EXELA PHARMA SCIENCES)

ELCYS (cysteine hydrochloride injection) is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN) and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. Each 10 mL of ELCYS contains 500 mg of cysteine hydrochloride, USP (equivalent to 345 mg of cysteine) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH range from 1.0 to 2.5.

For more information about ELCYS, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Oct. 1, 2019, through Dec. 31, 2019.

 
Calculate your current medicare IVIG/SCIG Rates
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Flebogamma J1572 $71.17 $70.03
Gammagard S/D J1566 $122.41 $120.44
Gammaplex J1557 $91.65 $90.18
Octagam J1568 $71.37 $70.22
Privigen J1459 $80.24 $78.96
SCIG
CUVITRU J1555 $137.87 $135.66
Hizentra J1559 $104.37 $102.70
HyQvia J1575 $145.56 $143.23
IVIG / SCIG
Gammagard Liquid J1569 $74.94 $73.73
Gammaked J1561 $78.28 $77.02
Gamunex-C J1561 $78.28 $77.02

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 
Log in to BioSupply for Immune Globulin Products

Resources

FFF customers may order the following complementary resources to help you with your practice:

Seasonal Flu Poster flu myths and facts brochure
immune globulin reference charts
•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to IG Living
IG Living Magazine cover
BioSupplyTrends Quarterly Magazine cover

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Subscribe to Biosupply Trends Quarterly Magazine
small Biosupply logo small MyFluVaccine logo Verified Inventory Program logo
Home | About | Advertise | Subscribe | Contact – ©FFF Enterprises, Inc.